Literature DB >> 10071127

Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.

M Kawamura1, H Ohnishi, S X Guo, X M Sheng, M Minegishi, R Hanada, K Horibe, T Hongo, Y Kaneko, F Bessho, M Yanagisawa, T Sekiya, Y Hayashi.   

Abstract

We investigated the alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia (T-ALL) and T-ALL cell lines by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis and direct sequencing. Mutations of the p53 gene were found in three of 57 (5%) patients at diagnosis, one of 14 (7%) patients at relapse and in 12 of 18 (67%) cell lines. In these 12 cell lines, four had more than two mutations of the p53 gene. The p53 mutations were found in four of five cell lines whose original fresh leukemic cells were simultaneously examined original fresh leukemic cells. However, only one of the four fresh leukemic cells had the same mutation. All patients with p53 mutations in the course of disease died. Mutations of the p21 gene were not identified in 71 fresh samples and in 18 cell lines. N-RAS mutations were found in two of 57 (4%) fresh T-ALL patients at diagnosis, and four of 18 cell lines (22%), whereas no mutations were detected in any samples at relapse. Alterations of the p16 gene were found in 18 of 47 (38%) patients at diagnosis and in seven of 14 (50%) at relapse. These differences were not statistically significant. There were no differences in the frequency of alteration of the p16 and p15 genes between event-free patients and the remaining patients. Furthermore, we found the methylation of p16 gene in three of seven patients lacking homozygous deletions, suggesting higher frequency of p16 inactivation than previous reports in T-ALL. Interestingly, we found that one allele is inactivated by methylation and another allele had nonsense mutation in one cell line (KOPT-KI), resulting in loss of protein expression of p16. This type of p16 inactivation has not been so far reported in leukemia. We conclude that, (1) p53 mutations are infrequent at diagnosis but tend to be associated with poor clinical outcome; (2) RAS and p21 mutations may not be involved in the pathogenesis of T-ALL; (3) not only frequent alterations of p16 and p15 genes but also methylation of p16 gene are involved in initiating the leukemogenesis of T-ALLs, and (4) these 5 genes are independently involved in T-ALL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071127     DOI: 10.1016/s0145-2126(98)00146-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  34 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

2.  Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array.

Authors:  Sarina Sulong
Journal:  Malays J Med Sci       Date:  2010-07

Review 3.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

5.  Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.

Authors:  David Krieger; Anja Moericke; Ilske Oschlies; Martin Zimmermann; Martin Schrappe; Alfred Reiter; Birgit Burkhardt
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

6.  Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.

Authors:  Qian Wang; Huiying Qiu; Hui Jiang; Lili Wu; Shasha Dong; Jinlan Pan; Wenjuan Wang; Nana Ping; Jing Xia; Aining Sun; Depei Wu; Yongquan Xue; Hans G Drexler; Roderick A F Macleod; Suning Chen
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

7.  TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Authors:  Sabina Chiaretti; Fulvia Brugnoletti; Simona Tavolaro; Silvia Bonina; Francesca Paoloni; Marilisa Marinelli; Nancy Patten; Massimiliano Bonifacio; Maria Grazia Kropp; Simona Sica; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

8.  Therapeutic targeting of HES1 transcriptional programs in T-ALL.

Authors:  Stephanie A Schnell; Alberto Ambesi-Impiombato; Marta Sanchez-Martin; Laura Belver; Luyao Xu; Yue Qin; Ryoichiro Kageyama; Adolfo A Ferrando
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

9.  Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation.

Authors:  Jessica S Blackburn; Sali Liu; Jayme L Wilder; Kimberly P Dobrinski; Riadh Lobbardi; Finola E Moore; Sarah A Martinez; Eleanor Y Chen; Charles Lee; David M Langenau
Journal:  Cancer Cell       Date:  2014-03-06       Impact factor: 31.743

10.  Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.

Authors:  Mark Y Chiang; Lanwei Xu; Olga Shestova; Gavin Histen; Sarah L'heureux; Candice Romany; M Eden Childs; Phyllis A Gimotty; Jon C Aster; Warren S Pear
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.